Peter Borchmann

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 245 publications

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

BrECADD in three days: Implementation of a condensed intensive first-line regimen in Hodgkin lymphoma.

Journal: British journal of haematology

Published: June 23, 2026

Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers.

Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers.

Journal: Future oncology (London, England)

Published: May 13, 2026

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.

Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.

Journal: Leukemia & lymphoma

Published: April 29, 2026

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

Journal: HemaSphere

Published: April 14, 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood

Published: April 01, 2026

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Prognostic impact of presentation phenotypes in early-stage favorable Hodgkin lymphoma.

Journal: Cancer

Published: March 21, 2026

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial.

Journal: Lancet (London, England)

Published: February 19, 2026

Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.

Brentuximab vedotin after alloSCT for relapsed/refractory Hodgkin lymphoma: GHSG BV-ALLO phase 2 trial.

Journal: Blood advances

Published: February 18, 2026

Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

Brentuximab Vedotin after AlloSCT for Relapsed/Refractory Hodgkin Lymphoma: GHSG BV-ALLO Phase II Trial.

Journal: Blood advances

Published: February 18, 2026

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma.

BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma.

Journal: JAMA oncology

Published: February 05, 2026

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses.

Journal: Blood advances

Published: February 05, 2026

Showing 1-12 of 245

Last Updated: 09/26/2026